The Supreme Court has blocked a sweeping set of restrictions on mifepristone access while the legal battle over the drug continues to wind through federal courts. The order came Thursday as the justices deadlocked over one of the year's most consequential healthcare disputes.
The decision freezes a lower court ruling that would have required patients to visit a doctor in person before receiving the abortion pill, effectively halting a major rollback of FDA rules that expanded remote prescribing and mail delivery. Those pathways now account for more than 60 percent of all abortions in the health system.
Drug manufacturers Danco Laboratories and GenBioPro brought the case to the high court after the 5th U.S. Circuit Court of Appeals sided with Louisiana, which challenged Biden administration policies it said undermined state protections for the unborn. The state also claimed it had to spend Medicaid dollars on emergency care related to the drug.
Justices Samuel Alito and Clarence Thomas dissented from the order. Alito argued that the manufacturers failed to demonstrate irreparable harm and suggested they could reapply for emergency protection if the FDA reversed course. Thomas revived a dormant argument centered on the Comcast Act, a 19th-century law he contended prohibits mailing the drug.
The Supreme Court declined to take up the full case immediately, instead returning it to the 5th Circuit. Legal observers expect the dispute to reach the justices again before long.
The ruling drew heavyweight attention throughout the judicial process. Former FDA commissioners, the pharmaceutical industry, state attorneys general, and lawmakers filed competing briefs. Critics of the lower court's decision warned it would expose the entire FDA drug approval system to state-by-state challenges.
The FDA is conducting a safety review of mifepristone. The agency said Thursday it would complete its analysis on a scientific basis and provide transparency updates as it progresses. Some anti-abortion groups accused the agency's previous leadership of slowing the review before former Commissioner Marty Makary resigned this week. His temporary replacement has taken a more vocal stance against abortion access.
Danco said it remains confident in mifepristone's safety profile and believes Louisiana's complaints should be dismissed outright.
Abortion rights advocates expressed relief but cautioned against overconfidence. Alexis McGill Johnson, president of Planned Parenthood Action Fund, called the order a bare minimum that provides near-term protection but does not guarantee long-term security. She warned of further legal assaults on reproductive care ahead.
Author James Rodriguez: "The Court punted on the harder question, but pharmacies and telehealth providers can now sleep at night knowing their mifepristone business won't evaporate tomorrow."
Comments